When do biologic drug patents expire and when will biosimilars launch?

US Patent 10,149,901 landscape: influenza vaccine unit dose 0.2–0.3 mL with squalene submicron oil-in-water emulsion adjuvant (≤19 mg/mL)

US 10,149,901 claims an influenza virus vaccine composition in a specified unit-dose volume (0.2–0.3 mL; often ~0.25 mL) that combines influenza A HA strains (H1 and/or H3) plus influenza B HA strains (Victoria and/or Yamagata lineage) with an oil-in-water emulsion adjuvant using submicron squalene droplets at ≤19 mg/mL (with multiple dependent claim ranges and discrete concentrations). The claim set is built for process-adjacent product protection (composition + dosage metrics + adjuvant lipid concentration) and for clinical performance via an immunogenicity/effectiveness-defined dependent claim.

The patent estate’s commercial leverage depends on (1) whether the market product uses squalene concentration and unit-dose volume within the claim boundaries, (2) whether it uses submicron oil-in-water emulsion droplets with polysorbate 80 and/or α-tocopherol, and (3) whether the product’s formulation is positioned for thiomersal-free / preservative-free and not egg-passaged antigen sources. Where competitors deviate on even one axis (unit dose outside 0.2–0.3 mL, squalene above 19 mg/mL, emulsion not “submicron,” or missing HA strain set), literal coverage can fall away, but doctrine-of-equivalents risk remains fact-dependent.

What are the key claim limitations in US 10,149,901 and how do they narrow coverage?

Immediate independent claim 1: the three “hard gates”

Claim 1 requires all of the following:

Influenza vaccine composition in unit dosage form with unit dose volume 0.2–0.3 mL.
Vaccine contains:
- At least one influenza A HA and at least one influenza B HA (lineage-specific dependent claims add granularity).
Uses an oil-in-water emulsion adjuvant with submicron oil droplets, where:
- Adjuvant comprises squalene
- Squalene concentration ≤ 19 mg/mL

This structure creates a high-friction infringement map: any candidate product must match the dose volume window and the squalene concentration ceiling, and must be an oil-in-water emulsion with submicron droplets (not merely an oil-in-water emulsion generally, and not a different adjuvant platform).

Dependent claims: what each one adds

Claim 2: at least two influenza A HA strains.
Claim 3: A HAs are H1 and H3 subtypes.
Claim 4: single influenza B HA is B/Victoria/2/87-like or B/Yamagata/16/88-like.
Claim 5: two A and two B HA strains (2+2).
Claim 6: explicitly recites H1N1 HA, H3N2 HA, B/Victoria/2/87-like, and B/Yamagata/16/88-like.
Claims 7, 8–12: tighter numeric constraints
- Unit dose volume “about 0.25 mL”
- Squalene concentration caps/ranges: ≤10 mg/mL, 2.5–19 mg/mL, 2.5–10 mg/mL, and discrete options 9.75 mg/mL and 4.88 mg/mL
- Squalene per dose: discrete amounts 2.7 mg, 2.4 mg, or 1.2 mg
Claims 13–15: hemagglutinin concentration and per-strain amounts
- HA concentration per strain: options including ≥12, ≥25, ≥30 µg/mL
- Example: about 30 µg/mL
- HA per strain: about 7.5 µg
Claim 16: adds formulation flexibilities and an additional ratio framing
- Equal HA concentration per strain and/or
- squalene:hemagglutinin weight ratio 20–180
- specifies antigen inactivated vaccine and antigen presentation modes: split virions, purified surface antigens, or virosomes
Claim 17–18: antigen sourcing / preservative status
- strains not passaged through eggs
- vaccine substantially free from mercurrial material
- thiomersal specifically (claim 18)
Claim 19: adjuvant formulation components
- polysorbate 80 and/or α-tocopherol
Claims 20–21: explicit embodiments
- Trivalent: H1N1 + H3N2 + one B lineage; two numeric “sets” for squalene concentration (9.75 vs 4.88 mg/mL), unit volume 0.25 mL; HA 30 µg/mL per strain
- Tetravalent: both B lineages with same squalene and unit-volume permutations
Claims 22–23: suitability for children (including ≤5 years old)
Claim 24: dependent “efficacy”/immunogenicity definition at scale
- In a population of at least 50 patients: elicits efficacy satisfying at least two among:
  - ≥70% seroprotection
  - ≥40% seroconversion or significant increase
  - ≥2.5-fold geometric mean titer increase

Practical effect: the “numerical matching” burden

Coverage is most likely to track the market product’s formulation choices:

Unit dose volume is a proxy for vial/syringe design and dosing instructions.
Squalene mg/mL is a direct proxy for the adjuvant formulation.
Submicron oil droplets is a proxy for manufacturing and adjuvant droplet size distribution.

Which influenza strain combinations are explicitly claimed in US 10,149,901?

A-strain HA coverage

Claim 3 locks A HAs to H1 and H3 subtypes.
Claim 6 locks to H1N1 and H3N2 HA.

Commercial implication: a product with only one A subtype or different A subtype selections may avoid dependent claim scope, but could still fall under claim 1 (which only requires at least one A HA).

B-strain HA coverage

Claim 4 lists B/Victoria/2/87-like and B/Yamagata/16/88-like for a single B HA.
Claim 6 locks to both B lineage-like antigens.

Commercial implication: the patent’s strongest multi-antigen embodiments align to products designed around both B lineages (tetravalent formulations) and classical HA heritage strains.

How does the squalene submicron emulsion adjuvant limit infringement risk?

Squalene concentration tiers that matter

Claim 1: ≤19 mg/mL.
Dependent tiers:

≤10 mg/mL (claim 8)
2.5–19 mg/mL (claim 9)
2.5–10 mg/mL (claim 10)
discrete examples: 9.75 mg/mL and 4.88 mg/mL (claim 11)
per-dose discrete squalene amounts: 2.7 mg, 2.4 mg, 1.2 mg (claim 12)

Infringement mapping: a competitor reformulating squalene toward a different mg/mL level can create a bright-line escape if outside ≤19 mg/mL and also outside the specific dependent ranges.

Submicron requirement: droplet-size language

The adjuvant is “oil-in-water emulsion with submicron oil droplets.”
This wording targets adjuvant architecture rather than just ingredients.

Design-around lever: a different droplet size distribution or a non-submicron emulsion can reduce literal correspondence to the “submicron” constraint.

Polysorbate 80 and α-tocopherol as optional add-ins

Claim 19 includes polysorbate 80 and/or α-tocopherol. Since “and/or” is used, inclusion of either can still meet claim 19, but claim 19 is dependent. A party could avoid claim 19 and still potentially meet earlier claims if those earlier limitations are present.

How are hemagglutinin dose and concentration constraints used to capture specific commercial schedules?

Per-strain and total HA concentration

Key dependent claims:

≥12 / ≥25 / ≥30 µg/mL per strain (claim 13)
about 30 µg/mL per strain (claim 14)
about 7.5 µg per strain (claim 15)
claim 16 can link weight ratio of squalene to hemagglutinin: 20–180

Why ratio matters

Even if a product matches squalene mg/mL and unit dose volume, squalene:HA weight ratio can still become a second check on infringement for claim 16-type coverage. If a competitor scales HA upward or downward without proportionally adjusting squalene, the ratio can move out of 20–180.

What does the egg-passaging, thiomersal-free, and preservative-free language do?

Egg passage limitation

Claim 17 requires the influenza virus strains have not been passaged through eggs (or potentially “and/or” depending on how claim 17 is construed, but it includes this as part of the claim’s listed alternatives).

Thiomersal / mercurial limitation

Claim 17 includes “substantially free from mercurial material” and/or “free of preservatives.”
Claim 18 specifically targets thiomersal.

Commercial implication: if a generic or rival product uses antigens produced by egg-based processes with measurable carryover, claim 17/18 scope narrows. However, the independent claim 1 does not include this manufacturing constraint, so infringement may still be possible under claim 1 if the product otherwise satisfies the composition and adjuvant limits.

Does the dependent efficacy/immunogenicity claim (claim 24) create clinical evidence leverage?

Claim 24 is a dependent claim that ties vaccine performance to thresholds in a cohort of at least 50 patients, requiring at least two metrics among:

≥70% seroprotection
≥40% seroconversion or significant increase
≥2.5-fold geometric mean titer increase

Legal/strategy implication: claim 24 can operate as an evidentiary hook in disputes if the accused product’s labeling, clinical study reports, or post-approval data demonstrate the thresholds. It is not a composition limitation like squalene mg/mL, so it functions more as a performance confirmation than a narrow product-design constraint.

What formulations are explicitly set out as embodiments in US 10,149,901?

Trivalent examples (claim 20)

Two “numerical sets”:

TIV set A: H1N1 + H3N2 + one B lineage; HA ~30 µg/mL per strain, squalene 9.75 mg/mL, unit dose ~0.25 mL
TIV set B: same but squalene 4.88 mg/mL

Tetravalent examples (claim 21)

Two “numerical sets” with both B lineages:

QIV set A: H1N1 + H3N2 + B/Yamagata + B/Victoria; HA ~30 µg/mL per strain, squalene 9.75 mg/mL, unit dose ~0.25 mL
QIV set B: same but squalene 4.88 mg/mL

These explicit embodiments indicate the patent is drafted around specific marketed concentrations rather than only broad ranges.

How does US 10,149,901 compare to typical flu vaccine IP estates (composition vs process vs clinical performance)?

This patent’s position in the usual flu vaccine IP stack

Influenza vaccine patents commonly cluster into:

antigen composition and subtype coverage,
adjuvant systems (oil-in-water emulsions, saponin-based, polymeric, etc.),
dose and unit volume specifics,
manufacturing/process controls (egg vs cell culture, purification/virion form),
clinical immunogenicity endpoints.

US 10,149,901 is weighted toward:

adjuvant composition and concentration (squalene mg/mL and submicron emulsion),
unit-dose volume (0.2–0.3 mL; ~0.25 mL),
antigen HA concentration and strain set (H1/H3 plus B lineages),
plus a clinical endpoint dependent claim (claim 24).

This combination increases the chance that competitors’ “near-miss” formulations still need to change multiple dimensions to escape.

When does US 10,149,901 lose exclusivity, and how does that drive launch risk?

A complete exclusivity timeline requires:

the patent’s filing date, priority date, and any patent term adjustment, and
whether it is tied to a specific regulatory exclusivity framework (e.g., orphan, pediatric, or reference product exclusivities), plus any PTA/terminal disclaimers.

Those elements are not present in the provided input, so a precise “expiration date” and exclusivity timeline cannot be computed from the claim text alone.

What patent litigation or FDA Orange Book risks attach to US 10,149,901?

A complete litigation and regulatory status analysis requires the patent’s links to:

the Orange Book listing (if applicable),
associated NDA/BLA numbers,
any PGR/CBM challenges,
and any district court matters involving the same formulation.

The provided input includes only claim text, not the patent’s bibliographic data (drug name, assignee, application number, related FDA approvals) or any litigation docket references. Without those, the infringement “risk map” cannot be tied to any specific marketed product or competitor.

Key Takeaways

US 10,149,901 protects a specific class of influenza vaccines defined by unit dose volume (0.2–0.3 mL) plus squalene submicron oil-in-water emulsion adjuvant with squalene concentration ≤19 mg/mL.
The strongest dependent coverage is for formulations combining H1 and H3 influenza A HA with B/Victoria and B/Yamagata-like influenza B HA, typically in tetravalent form.
Numeric constraints provide potential design-around levers: moving unit dose outside 0.2–0.3 mL and/or moving squalene above 19 mg/mL are the most direct escape paths from claim 1.
Dependent claims add additional narrowing through discrete squalene mg/mL examples (9.75 and 4.88 mg/mL), HA concentration per strain (~30 µg/mL) and per-strain HA (~7.5 µg), plus optional adjuvant components (polysorbate 80/α-tocopherol).
Claim 17/18 add manufacturing and formulation status constraints (no egg passage; thiomersal-free/preservative-free), while claim 24 adds a cohort immunogenicity definition that can function as an evidence hook.

FAQs

What changes most efficiently design around claim 1 of US 10,149,901?
Change the unit dose volume and/or increase squalene mg/mL above 19 and/or ensure the adjuvant is not an oil-in-water emulsion with submicron oil droplets.
Do H1/H3 and B Victoria/Yamagata strain selections matter for infringement?
They are required for the tighter dependent claims (not all are required for independent claim 1, which needs at least one A HA and at least one B HA).
How do the discrete squalene concentrations (9.75 and 4.88 mg/mL) affect competitive risk?
They strengthen coverage for products matching those example formulations; deviations can avoid the dependent-claim specifics even if the broader ≤19 mg/mL limitation remains met.
What role do thiomersal-free and egg-passaging statements play?
They narrow dependent claim scope tied to antigen sourcing and preservative status; they do not appear in independent claim 1 based on the provided claim set.
Can claim 24 be used without matching every composition limitation?
No, because it is dependent on claim 1 and its dependent chain; claim 24 adds performance requirements on top of the composition limitations.

References

Provided input: Claims text for US Patent 10,149,901 (user-supplied).

Title:	Influenza vaccines with reduced amounts of squalene
Abstract:	Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 .mu.g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
Inventor(s):	Contorni; Mario (Siena, IT), O\'Hagan; Derek (Cambridge, MA), Groth; Nicola (Buonconvento, IT)
Assignee:	Seqirus UK Limited (Berkshire, GB)
Application Number:	15/007,719
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 10,149,901 landscape: influenza vaccine unit dose 0.2–0.3 mL with squalene submicron oil-in-water emulsion adjuvant (≤19 mg/mL) US 10,149,901 claims an influenza virus vaccine composition in a specified unit-dose volume (0.2–0.3 mL; often ~0.25 mL) that combines influenza A HA strains (H1 and/or H3) plus influenza B HA strains (Victoria and/or Yamagata lineage) with an oil-in-water emulsion adjuvant using submicron squalene droplets at ≤19 mg/mL (with multiple dependent claim ranges and discrete concentrations). The claim set is built for process-adjacent product protection (composition + dosage metrics + adjuvant lipid concentration) and for clinical performance via an immunogenicity/effectiveness-defined dependent claim. The patent estate’s commercial leverage depends on (1) whether the market product uses squalene concentration and unit-dose volume within the claim boundaries, (2) whether it uses submicron oil-in-water emulsion droplets with polysorbate 80 and/or α-tocopherol, and (3) whether the product’s formulation is positioned for thiomersal-free / preservative-free and not egg-passaged antigen sources. Where competitors deviate on even one axis (unit dose outside 0.2–0.3 mL, squalene above 19 mg/mL, emulsion not “submicron,” or missing HA strain set), literal coverage can fall away, but doctrine-of-equivalents risk remains fact-dependent. What are the key claim limitations in US 10,149,901 and how do they narrow coverage? Immediate independent claim 1: the three “hard gates” Claim 1 requires all of the following: Influenza vaccine composition in unit dosage form with unit dose volume 0.2–0.3 mL. Vaccine contains: At least one influenza A HA and at least one influenza B HA (lineage-specific dependent claims add granularity). Uses an oil-in-water emulsion adjuvant with submicron oil droplets, where: Adjuvant comprises squalene Squalene concentration ≤ 19 mg/mL This structure creates a high-friction infringement map: any candidate product must match the dose volume window and the squalene concentration ceiling, and must be an oil-in-water emulsion with submicron droplets (not merely an oil-in-water emulsion generally, and not a different adjuvant platform). Dependent claims: what each one adds Claim 2: at least two influenza A HA strains. Claim 3: A HAs are H1 and H3 subtypes. Claim 4: single influenza B HA is B/Victoria/2/87-like or B/Yamagata/16/88-like. Claim 5: two A and two B HA strains (2+2). Claim 6: explicitly recites H1N1 HA, H3N2 HA, B/Victoria/2/87-like, and B/Yamagata/16/88-like. Claims 7, 8–12: tighter numeric constraints Unit dose volume “about 0.25 mL” Squalene concentration caps/ranges: ≤10 mg/mL, 2.5–19 mg/mL, 2.5–10 mg/mL, and discrete options 9.75 mg/mL and 4.88 mg/mL Squalene per dose: discrete amounts 2.7 mg, 2.4 mg, or 1.2 mg Claims 13–15: hemagglutinin concentration and per-strain amounts HA concentration per strain: options including ≥12, ≥25, ≥30 µg/mL Example: about 30 µg/mL HA per strain: about 7.5 µg Claim 16: adds formulation flexibilities and an additional ratio framing Equal HA concentration per strain and/or squalene:hemagglutinin weight ratio 20–180 specifies antigen inactivated vaccine and antigen presentation modes: split virions, purified surface antigens, or virosomes Claim 17–18: antigen sourcing / preservative status strains not passaged through eggs vaccine substantially free from mercurrial material thiomersal specifically (claim 18) Claim 19: adjuvant formulation components polysorbate 80 and/or α-tocopherol Claims 20–21: explicit embodiments Trivalent: H1N1 + H3N2 + one B lineage; two numeric “sets” for squalene concentration (9.75 vs 4.88 mg/mL), unit volume 0.25 mL; HA 30 µg/mL per strain Tetravalent: both B lineages with same squalene and unit-volume permutations Claims 22–23: suitability for children (including ≤5 years old) Claim 24: dependent “efficacy”/immunogenicity definition at scale In a population of at least 50 patients: elicits efficacy satisfying at least two among: ≥70% seroprotection ≥40% seroconversion or significant increase ≥2.5-fold geometric mean titer increase Practical effect: the “numerical matching” burden Coverage is most likely to track the market product’s formulation choices: Unit dose volume is a proxy for vial/syringe design and dosing instructions. Squalene mg/mL is a direct proxy for the adjuvant formulation. Submicron oil droplets is a proxy for manufacturing and adjuvant droplet size distribution. Which influenza strain combinations are explicitly claimed in US 10,149,901? A-strain HA coverage Claim 3 locks A HAs to H1 and H3 subtypes. Claim 6 locks to H1N1 and H3N2 HA. Commercial implication: a product with only one A subtype or different A subtype selections may avoid dependent claim scope, but could still fall under claim 1 (which only requires at least one A HA). B-strain HA coverage Claim 4 lists B/Victoria/2/87-like and B/Yamagata/16/88-like for a single B HA. Claim 6 locks to both B lineage-like antigens. Commercial implication: the patent’s strongest multi-antigen embodiments align to products designed around both B lineages (tetravalent formulations) and classical HA heritage strains. How does the squalene submicron emulsion adjuvant limit infringement risk? Squalene concentration tiers that matter Claim 1: ≤19 mg/mL. Dependent tiers: ≤10 mg/mL (claim 8) 2.5–19 mg/mL (claim 9) 2.5–10 mg/mL (claim 10) discrete examples: 9.75 mg/mL and 4.88 mg/mL (claim 11) per-dose discrete squalene amounts: 2.7 mg, 2.4 mg, 1.2 mg (claim 12) Infringement mapping: a competitor reformulating squalene toward a different mg/mL level can create a bright-line escape if outside ≤19 mg/mL and also outside the specific dependent ranges. Submicron requirement: droplet-size language The adjuvant is “oil-in-water emulsion with submicron oil droplets.” This wording targets adjuvant architecture rather than just ingredients. Design-around lever: a different droplet size distribution or a non-submicron emulsion can reduce literal correspondence to the “submicron” constraint. Polysorbate 80 and α-tocopherol as optional add-ins Claim 19 includes polysorbate 80 and/or α-tocopherol. Since “and/or” is used, inclusion of either can still meet claim 19, but claim 19 is dependent. A party could avoid claim 19 and still potentially meet earlier claims if those earlier limitations are present. How are hemagglutinin dose and concentration constraints used to capture specific commercial schedules? Per-strain and total HA concentration Key dependent claims: ≥12 / ≥25 / ≥30 µg/mL per strain (claim 13) about 30 µg/mL per strain (claim 14) about 7.5 µg per strain (claim 15) claim 16 can link weight ratio of squalene to hemagglutinin: 20–180 Why ratio matters Even if a product matches squalene mg/mL and unit dose volume, squalene:HA weight ratio can still become a second check on infringement for claim 16-type coverage. If a competitor scales HA upward or downward without proportionally adjusting squalene, the ratio can move out of 20–180. What does the egg-passaging, thiomersal-free, and preservative-free language do? Egg passage limitation Claim 17 requires the influenza virus strains have not been passaged through eggs (or potentially “and/or” depending on how claim 17 is construed, but it includes this as part of the claim’s listed alternatives). Thiomersal / mercurial limitation Claim 17 includes “substantially free from mercurial material” and/or “free of preservatives.” Claim 18 specifically targets thiomersal. Commercial implication: if a generic or rival product uses antigens produced by egg-based processes with measurable carryover, claim 17/18 scope narrows. However, the independent claim 1 does not include this manufacturing constraint, so infringement may still be possible under claim 1 if the product otherwise satisfies the composition and adjuvant limits. Does the dependent efficacy/immunogenicity claim (claim 24) create clinical evidence leverage? Claim 24 is a dependent claim that ties vaccine performance to thresholds in a cohort of at least 50 patients, requiring at least two metrics among: ≥70% seroprotection ≥40% seroconversion or significant increase ≥2.5-fold geometric mean titer increase Legal/strategy implication: claim 24 can operate as an evidentiary hook in disputes if the accused product’s labeling, clinical study reports, or post-approval data demonstrate the thresholds. It is not a composition limitation like squalene mg/mL, so it functions more as a performance confirmation than a narrow product-design constraint. What formulations are explicitly set out as embodiments in US 10,149,901? Trivalent examples (claim 20) Two “numerical sets”: TIV set A: H1N1 + H3N2 + one B lineage; HA ~30 µg/mL per strain, squalene 9.75 mg/mL, unit dose ~0.25 mL TIV set B: same but squalene 4.88 mg/mL Tetravalent examples (claim 21) Two “numerical sets” with both B lineages: QIV set A: H1N1 + H3N2 + B/Yamagata + B/Victoria; HA ~30 µg/mL per strain, squalene 9.75 mg/mL, unit dose ~0.25 mL QIV set B: same but squalene 4.88 mg/mL These explicit embodiments indicate the patent is drafted around specific marketed concentrations rather than only broad ranges. How does US 10,149,901 compare to typical flu vaccine IP estates (composition vs process vs clinical performance)? This patent’s position in the usual flu vaccine IP stack Influenza vaccine patents commonly cluster into: antigen composition and subtype coverage, adjuvant systems (oil-in-water emulsions, saponin-based, polymeric, etc.), dose and unit volume specifics, manufacturing/process controls (egg vs cell culture, purification/virion form), clinical immunogenicity endpoints. US 10,149,901 is weighted toward: adjuvant composition and concentration (squalene mg/mL and submicron emulsion), unit-dose volume (0.2–0.3 mL; ~0.25 mL), antigen HA concentration and strain set (H1/H3 plus B lineages), plus a clinical endpoint dependent claim (claim 24). This combination increases the chance that competitors’ “near-miss” formulations still need to change multiple dimensions to escape. When does US 10,149,901 lose exclusivity, and how does that drive launch risk? A complete exclusivity timeline requires: the patent’s filing date, priority date, and any patent term adjustment, and whether it is tied to a specific regulatory exclusivity framework (e.g., orphan, pediatric, or reference product exclusivities), plus any PTA/terminal disclaimers. Those elements are not present in the provided input, so a precise “expiration date” and exclusivity timeline cannot be computed from the claim text alone. What patent litigation or FDA Orange Book risks attach to US 10,149,901? A complete litigation and regulatory status analysis requires the patent’s links to: the Orange Book listing (if applicable), associated NDA/BLA numbers, any PGR/CBM challenges, and any district court matters involving the same formulation. The provided input includes only claim text, not the patent’s bibliographic data (drug name, assignee, application number, related FDA approvals) or any litigation docket references. Without those, the infringement “risk map” cannot be tied to any specific marketed product or competitor. Key Takeaways US 10,149,901 protects a specific class of influenza vaccines defined by unit dose volume (0.2–0.3 mL) plus squalene submicron oil-in-water emulsion adjuvant with squalene concentration ≤19 mg/mL. The strongest dependent coverage is for formulations combining H1 and H3 influenza A HA with B/Victoria and B/Yamagata-like influenza B HA, typically in tetravalent form. Numeric constraints provide potential design-around levers: moving unit dose outside 0.2–0.3 mL and/or moving squalene above 19 mg/mL are the most direct escape paths from claim 1. Dependent claims add additional narrowing through discrete squalene mg/mL examples (9.75 and 4.88 mg/mL), HA concentration per strain (~30 µg/mL) and per-strain HA (~7.5 µg), plus optional adjuvant components (polysorbate 80/α-tocopherol). Claim 17/18 add manufacturing and formulation status constraints (no egg passage; thiomersal-free/preservative-free), while claim 24 adds a cohort immunogenicity definition that can function as an evidence hook. FAQs What changes most efficiently design around claim 1 of US 10,149,901? Change the unit dose volume and/or increase squalene mg/mL above 19 and/or ensure the adjuvant is not an oil-in-water emulsion with submicron oil droplets. Do H1/H3 and B Victoria/Yamagata strain selections matter for infringement? They are required for the tighter dependent claims (not all are required for independent claim 1, which needs at least one A HA and at least one B HA). How do the discrete squalene concentrations (9.75 and 4.88 mg/mL) affect competitive risk? They strengthen coverage for products matching those example formulations; deviations can avoid the dependent-claim specifics even if the broader ≤19 mg/mL limitation remains met. What role do thiomersal-free and egg-passaging statements play? They narrow dependent claim scope tied to antigen sourcing and preservative status; they do not appear in independent claim 1 based on the provided claim set. Can claim 24 be used without matching every composition limitation? No, because it is dependent on claim 1 and its dependent chain; claim 24 adds performance requirements on top of the composition limitations. References Provided input: Claims text for US Patent 10,149,901 (user-supplied). More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	November 03, 1998	⤷ Start Trial	2036-01-27
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	December 09, 1999	⤷ Start Trial	2036-01-27
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	December 23, 2009	⤷ Start Trial	2036-01-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,149,901

Summary for Patent: 10,149,901